ClinicalTrials.gg
RecruitingNCT05561634RADIOSONICUpdated Sep 30, 2025

Radiotherapy by Sonic Hedgehog Pathway Inhibitors in Basal Cell Carcinoma

A Phase 2 interventional study of Radiotherapy and Observation in Basal Cell Carcinoma and Radiotherapy; Complications, sponsored by University Hospital, Lille. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-30.

Sponsored by University Hospital, Lille · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
82
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies testing HhAntag691 in Carcinoma, Basal Cell — 1 open to participants now, 1 under way, none of them phase 3. HhAntag691 · Carcinoma, Basal Cell.

Planned enrollment
4th of 19
82 · median 28
Started
2023
the only one that year
Phase 2
14 of 19
1 open now
Registered
19th of 19
by date
Lead sponsor
2 of 19
University Hospital, Lille

Among the 19 studies testing HhAntag691 in Carcinoma, Basal Cell, this one is the 4th largest by planned enrollment, is the only one that started in 2023, is one of 14 in phase 2, and was the 19th registered.

Carcinoma, Basal Cell

389 studies on the registry are indexed under Carcinoma, Basal Cell; 69 are open to participants now.

Browse Carcinoma, Basal Cell studies →

Open to participants now

1 of the 19 studies testing HhAntag691 in Carcinoma, Basal Cell is open now, in 1 country.

By country, each count listing its studies:

About HhAntag691

HhAntag691: first FDA approval 2012 (ERIVEDGE), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 53 Carcinoma, Basal Cell studies recruiting now, 49 (92%) set no upper age limit and none (0%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing HhAntag691 in Carcinoma, Basal Cell, or all of them as a file.
02

Study summary

Locally advanced basal cell carcinoma (BCC) are large BCCs or BCCs located in areas subject to functional and aesthetic risk following surgery or radiotherapy. In these particular situations, surgery and radiotherapy are sometimes not appropriate, and Sonic Hedgehog inhibitors (SHHi) (Vismodegib and Sonidegib) can be proposed. SHHi are effective treatments in laBCC but most CR patients discontinue treatment because of tolerability. Approximately 65% of the population experience a relapse after discontinuation. A few cases of patients treated concomitantly by radiotherapy and vismodegib have been reported in the literature, suggesting that combining vismodegib and concomitant radiotherapy results in an improved overall response compared to a single modality treatment. There is no study evaluating a "consolidation radiotherapy" after complete response to SHHi. We carry out a prospective multicenter study in order to evaluate consolidation radiotherapy in patients with laBCC after achieving complete response with SHHi, with the hypothesis of reducing recurrence after discontinuation of SHHi.

03

Conditions studied

  • Basal Cell Carcinoma
  • Radiotherapy; Complications

Browse trials for

Keywords

  • Locally advanced basal cell carcinoma
  • Sonic Hedgehog inhibitors
  • Consideration radiotherapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient over 18 years
  • Locally advanced non-recurrent BCC in complete response after first course of SHHi
  • Complete response has to be confirmed histologically
  • Available photography or CT scan before SHHi treatment allowing delineation of the initial tumor

Exclusion criteria

Exclusion Criteria:

  • Patients with distant
  • Patients with Gorlin's syndrome
  • Prior radiotherapy to the region of the studied cancer that would result in overlap of radiation therapy fields
  • Pregnant women
  • less than 1 year
  • Inability to receive
  • Inability to participate in the entire study
  • Lack of social security coverage
  • Refusal to sign consent
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
82 participants (estimated)

Study arms

  • Sham comparator
    SHHI then follow-up

    Radiation: Radiotherapy · Other: Observation

  • Experimental
    SHHI then radiotherapy

    Radiation: Radiotherapy · Drug: Vismodegib

Interventions

  • RadiationRadiotherapy

    Irradiation of the tumoral bed.

  • OtherObservation

    Patients will be followed up in consultation every 3 months.

  • DrugHhAntag691Studies of HhAntag691HhAntag691 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Sonic Hedgehog inhibitors (SHHi) = Vismodegib et Sonidegib,

06

What researchers measure

Primary outcomes

  1. Occurrence of a local relapse at 2 years in both groups.

    Time frame: At 2 years

Secondary outcomes

  1. Occurrence of local relapse at 1 and 3 years.

    Time frame: at 1 year and at 3 years

  2. Occurrence of adverse effects in the radiotherapy group.

    Time frame: at 1 year, at 2 years and at 3 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Jun 2029, 72 months after the start.

Of 44 phase 2 interventional studies under Carcinoma, Basal Cell, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 67. This study's planned 72 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2022
First posted
Sep 30, 2022
StartActual
Jun 20, 2023
Primary completionEst.
Jun 20, 2029
CompletionEst.
Jun 20, 2029
Last update
Sep 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05561634
Responsible party
Sponsor
First posted
Sep 30, 2022
Start date
Jun 20, 2023
Primary completion
Jun 20, 2029 (estimated)
Completion
Jun 20, 2029 (estimated)
Last update
Sep 30, 2025

Study contacts

Laurent Mortier, MD,PhD
Contact
laurent.mortier@chru-lille.fr
0320445962
Laurent Mortier, MD,PhD
principal investigator · University Hospital, Lille

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HhAntag691

Start the discussion